Unknown

Dataset Information

0

Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.


ABSTRACT: Strategies to treat cancer have focused primarily on the killing of tumor cells. Here, we describe a differential stress resistance (DSR) method that focuses instead on protecting the organism but not cancer cells against chemotherapy. Short-term starved S. cerevisiae or cells lacking proto-oncogene homologs were up to 1,000 times better protected against oxidative stress or chemotherapy drugs than cells expressing the oncogene homolog Ras2(val19). Low-glucose or low-serum media also protected primary glial cells but not six different rat and human glioma and neuroblastoma cancer cell lines against hydrogen peroxide or the chemotherapy drug/pro-oxidant cyclophosphamide. Finally, short-term starvation provided complete protection to mice but not to injected neuroblastoma cells against a high dose of the chemotherapy drug/pro-oxidant etoposide. These studies describe a starvation-based DSR strategy to enhance the efficacy of chemotherapy and suggest that specific agents among those that promote oxidative stress and DNA damage have the potential to maximize the differential toxicity to normal and cancer cells.

SUBMITTER: Raffaghello L 

PROVIDER: S-EPMC2448817 | biostudies-other | 2008 Jun

REPOSITORIES: biostudies-other

altmetric image

Publications

Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.

Raffaghello Lizzia L   Lee Changhan C   Safdie Fernando M FM   Wei Min M   Madia Federica F   Bianchi Giovanna G   Longo Valter D VD  

Proceedings of the National Academy of Sciences of the United States of America 20080331 24


Strategies to treat cancer have focused primarily on the killing of tumor cells. Here, we describe a differential stress resistance (DSR) method that focuses instead on protecting the organism but not cancer cells against chemotherapy. Short-term starved S. cerevisiae or cells lacking proto-oncogene homologs were up to 1,000 times better protected against oxidative stress or chemotherapy drugs than cells expressing the oncogene homolog Ras2(val19). Low-glucose or low-serum media also protected p  ...[more]

Similar Datasets

| S-EPMC7477630 | biostudies-literature
| S-EPMC6812053 | biostudies-literature
| S-EPMC1088964 | biostudies-literature
| 2202552 | ecrin-mdr-crc
2013-02-01 | E-MEXP-3523 | biostudies-arrayexpress
| S-EPMC5553613 | biostudies-literature
| S-EPMC4491046 | biostudies-literature
| S-EPMC1386026 | biostudies-other
| S-EPMC2567878 | biostudies-other
| S-EPMC6811995 | biostudies-other